Welcome to our dedicated page for Kiromic Biopharma news (Ticker: KRBP), a resource for investors and traders seeking the latest updates and insights on Kiromic Biopharma stock.
Kiromic BioPharma, Inc. (OTCQB: KRBP) is a clinical-stage biotherapeutics company focused on immuno-oncology, and the KRBP news page highlights company announcements, clinical updates and regulatory milestones. Kiromic is developing a multi-indication allogeneic cell therapy platform that uses gamma delta T-cells to target solid tumors, with its lead investigational product Deltacel™ (KB-GDT-01) in a Phase 1 trial for stage 4 non-small cell lung cancer (NSCLC) that has failed standard therapies.
News items for KRBP frequently cover progress in the Deltacel-01 clinical trial, including safety observations, tumor volume changes, partial responses, stable disease assessments and progression-free survival data in individual patients. The company also reports on decisions from the Deltacel-01 Safety Monitoring Committee, transitions from initial cohorts into expansion phases, and the activation of additional clinical trial sites such as the Beverly Hills Cancer Center, Texas Oncology in Tyler, Virginia Oncology Associates and the University of Arizona Cancer Center.
Regulatory and corporate developments appear in this feed as well, including Kiromic’s announcement that the U.S. Food and Drug Administration granted Fast Track designation to Deltacel in combination with low-dose radiation for certain metastatic NSCLC patients, and the company’s disclosure of a settlement agreement with the U.S. Securities and Exchange Commission related to prior non-disclosure of FDA clinical holds.
Investors and observers can use the KRBP news page to follow Kiromic’s ongoing clinical results, site expansions, regulatory designations and corporate updates related to its gamma delta T-cell platform and DIAMOND® AI 2.0 target discovery engine. Regular review of this page can help track how the Deltacel-01 program and Kiromic’s broader immuno-oncology strategy evolve over time.
Kiromic BioPharma (OTCQB: KRBP) has reported favorable eight-month follow-up results from the first patient in its Deltacel-01 Phase 1 clinical trial. The trial is evaluating Deltacel™ (KB-GDT-01), an allogeneic, off-the-shelf, Gamma Delta T-cell therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed standard therapies.
Key findings include:
- 20% tumor size reduction at eight months post-treatment
- No new tumor lesions detected
- Eight-month progression-free survival
- Improvement from 13% reduction at six months post-treatment
The patient is being treated at the Beverly Hills Cancer Center. Kiromic expects to report additional follow-up results from the fourth and fifth patients in August.
Kiromic BioPharma (OTCQB: KRBP) is advancing its Deltacel-01 Phase 1 clinical trial to the Expansion Phase following a positive assessment from the Safety Monitoring Committee. The trial evaluates Deltacel™, an allogeneic, off-the-shelf, Gamma Delta T-cell therapy for stage 4 metastatic non-small cell lung cancer patients who have failed standard therapies. The company plans to begin enrolling patients in the Expansion Phase in September, adding nine more patients to the trial.
The fifth patient in Deltacel-01 completed their 30-day visit with a favorable safety profile and no dose-limiting toxicities. Kiromic expects to report early efficacy data from this patient's two-month follow-up in August. The trial's progress marks a significant milestone in validating Kiromic's innovative gamma delta approach to cancer treatment.
Kiromic BioPharma (OTCQB: KRBP) has provided updates on its Deltacel-01 Phase 1 clinical trial, which focuses on advanced non-small cell lung cancer (NSCLC) patients non-responsive to standard treatments. The trial features Deltacel (KB-GDT-01), an allogeneic Gamma Delta T-cell therapy. Patients three and four showed stable disease at follow-ups with no dose-limiting toxicities. The second patient had a complete response in brain metastasis but later detected a new subcutaneous metastasis; a new treatment protocol has been approved by the FDA. Kiromic has also submitted a Fast Track designation request to the FDA, possibly accelerating Deltacel's development. Additionally, a fifth patient completed their safety visit with no toxicities, while the sixth patient is anticipated to enroll in July.
Kiromic BioPharma (OTCQB: KRBP) has released promising six-month follow-up results for the first patient in the Deltacel-01 Phase 1 clinical trial. This trial assesses Deltacel™ (KB-GDT-01), an off-the-shelf Gamma Delta T-cell therapy for stage 4 metastatic non-small cell lung cancer (NSCLC). The patient showed a 13% tumor reduction and no new lesions, resulting in six-month progression-free survival. No dose-limiting toxicities were reported, confirming Deltacel's safety. Kiromic plans to report further long-term results by the end of June and continues to enroll new patients in the trial.
Kiromic BioPharma (OTCQB: KRBP) reported favorable six-week results from the fourth patient in its Deltacel-01 Phase 1 clinical trial. This trial evaluates the allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy, Deltacel™ (KB-GDT-01), in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who didn't respond to standard treatments. Preliminary results show an 8.5% reduction in tumor size and no new metastatic disease sites, indicating promising early efficacy. The patient also experienced improved quality of life, including discontinuation of prescription pain medications. CEO Pietro Bersani expressed optimism about these initial findings and the upcoming results from the remaining patients in the second cohort, expected in June.
Kiromic BioPharma has announced that UPMC in Pittsburgh, PA, is now the fourth clinical trial site for their Deltacel-01 Phase 1 trial. This trial evaluates Deltacel™ (KB-GDT-01), an allogeneic, off-the-shelf, Gamma Delta T-cell therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC). Dr. Jason J. Luke, a leading expert in immuno-oncology, will serve as the principal investigator at UPMC. Preliminary safety and tolerability data from the fourth patient in Deltacel-01 are favorable, with early efficacy data expected by the end of May. The company plans to enroll the fifth and sixth patients in May and June, respectively, and activate one more trial site later this quarter.
Summary not available.
Summary not available.
Summary not available.
Summary not available.